// App-Quantinova.ai

1250 : Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

Researchers

Presenter

  • Mark W. Drummond

Principal Investigators

  • Charlotte Gaskell

  • Claire Harrison

  • Adam J. Mead

  • Christina Yap

  • Aimee E Jackson

  • Jennifer Byrne

  • Fiona J Clark

  • Srinivasan Narayanan

  • David Bowen

  • Tim C.P Somervaille

  • Emma Gudgin

  • Dragana Milojkovic

  • Rachel S Fletcher

  • Charlotte K Brierley

  • Steve Knapper

Medical Centers

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • IGF Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

  • Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • Queen Elizabeth Hospital - Histopathology - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Haematology, University Hospital Southampton, Southampton, United Kingdom

  • St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • The Christie Hospital, Cancer Research UK Manchester Institute, Manchester, United Kingdom

  • Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Department of Haematology, Hammersmith Hospital, Imperial Healthcare NHS Trust, London, United Kingdom

  • Weatherall Institute of Molecular Medicine, Oxford, United Kingdom

  • Institute of Cancer & Genetics, Cardiff University, Cardiff, Wales, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Myelodysplastic Syndrome

  • Acute myelocytic leukemia

  • Acute Leukemia

  • Neutropenia

  • Sepsis

Biomarkers

  • Calreticulin

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Red Blood Cells

Drug/Treatment

  • Vidaza

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Single Arm

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved